The Effect of Liposomal Bupivacaine Erector Spinae Plane Block (NCT07667439) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
The Effect of Liposomal Bupivacaine Erector Spinae Plane Block
China148 participantsStarted 2026-07-01
Plain-language summary
This is a single-center, randomized, controlled, double-blind clinical trial. A total of 148 patients undergoing elective open upper abdominal surgery will be included and randomly assigned 1:1 to receive ultrasound-guided erector spinae plane block with liposome bupivacaine plus bupivacaine hydrochloride or bupivacaine hydrochloride alone. The primary outcome is the AUC of resting pain scores from 0 to 72 hours postoperatively. This study aims to evaluate the analgesic efficacy and safety of liposome bupivacaine and provide a long-acting and safe postoperative analgesia strategy.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Patients scheduled for elective open upper abdominal surgery, including open liver, gastric and pancreatic surgery.
. Patients receiving general anesthesia with tracheal intubation.
. Aged from 18 to 80 years old.
. Patients with American Society of Anesthesiologists (ASA) physical status class Ⅰ-Ⅲ.
. Patients who can understand the trial content, are willing to strictly follow the clinical research protocol and complete the trial, and voluntarily sign the informed consent form.
Exclusion criteria
. Pregnant or lactating women.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
AUC of resting pain score within 0-72 hours after operation
Timeframe: Postoperative 0 to 72 hours
Trial details
NCT IDNCT07667439
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
. Patients complicated with severe primary diseases of the lung, liver, kidney, cardiovascular system and hematopoietic system.
. Bleeding tendency or coagulation dysfunction, defined as international normalized ratio (INR) ≥ 1.4, activated partial thromboplastin time \> 38 s, or platelet count \< 80×10⁹/L.
. Patients with aggravated cardiac diseases (complex congenital heart disease, heart failure and valvular disease) or pulmonary insufficiency.
. Skin infection at the puncture site for erector spinae plane block (ESPB).
. Previous history of neurological or psychiatric diseases, with inability to read, understand and communicate.
. Current obstructive or restrictive pulmonary disease.